Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of synapse function

Patent metadata

Field	Value
Publication number	US-2016136136-A1
Application number	US-201514954388-A
Country	US
Kind code	A1
Filing date	Nov 30, 2015
Priority date	Apr 29, 2008
Publication date	May 19, 2016
Grant date	—

Abstract

Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.

First claim

1 . A composition comprising zonisamide, or a salt, prodrug, derivative, or sustained release formulation thereof, for treating Alzheimer's disease (AD) in a subject in need thereof.

2 . The composition of claim 1 , further comprising at least one compound selected from the group of dyphylline, tadalafil, argatroban, acamprosate, cinacalcet, terbinafine, cilostazol, baclofen, phenformin, amlodipine and sulfisoxazole, or salts or prodrugs or derivatives or sustained release formulations thereof, for combined, separate or sequential administration with zonisamide.

3 . The composition of claim 2 , wherein said composition comprises at least one of the following drug combinations, said drugs in each of said combinations being for combined, separate or sequential administration:
phenformin and zonisamide, zonisamide and sulfisoxazole, acamprosate and zonisamide, zonisamide and dyphylline, zonisamide and argatroban, zonisamide and cilostazol, or zonisamide and terbinafine.

4 . The composition of claim 2 , wherein said composition further comprises at least one drug that modulates synapse function, for combined, separate or sequential use.

5 . The composition of claim 2 , wherein said composition further comprises at least one drug that modulates angiogenesis, for combined, separate or sequential use.

6 . The composition of claim 2 , wherein said composition further comprises at least one drug that modulates cell stress response, for combined, separate or sequential use.

7 . The composition of claim 1 , which comprises a pharmaceutically acceptable carrier or excipient.

8 . The composition of claim 1 , wherein said composition is administered repeatedly to the subject.

9 . A composition comprising at least one of the following drug combinations, said drugs in each of said combinations being for combined, separate or sequential administration:
phenformin and zonisamide, zonisamide and sulfisoxazole, acamprosate and zonisamide, zonisamide and dyphylline, zonisamide and argatroban, zonisamide and cilostazol, or zonisamide and terbinafine.

10 . A composition comprising at least phenformin, or a salt, prodrug, derivative, or sustained release formulation thereof, for treating Alzheimer's disease in a subject in need thereof.

11 . The composition of claim 10 , wherein said composition comprises at least one of the following drug combinations, said drugs in each of said combinations being for combined, separate or sequential administration:
phenformin and acamprosate, phenformin and sulfisoxazole, phenformin and dyphylline, phenformin and cilostazol, or phenformin and tadalafil.

12 . A composition comprising at least one of the following drug combinations, said drugs in each of said combinations being for combined, separate or sequential administration:
phenformin and acamprosate, phenformin and sulfisoxazole, phenformin and dyphylline, phenformin and cilostazol, or phenformin and tadalafil.

13 . A method of treating Alzheimer's disease, the method comprising administering to a subject in need thereof an effective amount of zonisamide, or a salt or a sustained release formulation thereof, and at least one compound chosen from the group consisting of dyphylline, tadalafil, argatroban, cinacalcet, terbinafine, cilostazol, baclofen, phenformin, amlodipine, sulfisoxazole, and salts or sustained release formulations thereof.

14 . The method of claim 13 , wherein the at least one compound is dyphylline, argatroban, terbinafine, cilostazol, phenformin, sulfisoxazole, or salts or sustained release formulations thereof.

15 . The method of claim 13 , further comprising simultaneously, separately, or sequentially administering to a subject in need thereof a drug that modulates synapse function.

16 . The method of claim 13 , further comprising simultaneously, separately, or sequentially administering to a subject in need thereof a drug that modulates angiogenesis.

17 . The method of claim 13 , further comprising simultaneously, separately, or sequentially administering to a subject in need thereof a drug that modulates cell stress response.

18 . The method of claim 13 , wherein the effective amount of zonisamide, or a salt or a sustained release formulation thereof, is formulated with a pharmaceutically acceptable carrier or excipient.

19 . The method of claim 13 , wherein the effective amount of zonisamide, or a salt or a sustained release formulation thereof, is repeatedly administered to the subject.

20 . The method of claim 13 , wherein the compounds are administered separately.

21 . The method of claim 13 , wherein the compounds are administered sequentially.

22 . The method of claim 13 , wherein the compounds are administered simultaneously.

Assignees

• Pharnext

Inventors

• Cohen Daniel
• Chumakov Ilya
• Nabirochkin Serguei
• Guerassimenko Oxana
• Cholet Nathalie

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D261/20

  condensed with carbocyclic rings or ring systems · CPC title